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Abstract
Iron deficiency is a common nutritional disorder in developing countries and contrib‐
utes significantly to reduced work productivity and economic output as well as to
increased morbidity and mortality. There are well-established biochemical tests for
assessing iron status in developed countries.  However,  cost  and interference from
infectious conditions make it difficult to assess iron status in many developing country
settings. Examination of the hemoglobin distribution in the population and assess‐
ment of the hemoglobin response to supplementation are alternative approaches to
define iron status and the nature of anemia. Prevention and control of iron deficiency
requires the combined approach of dietary improvement, fortification of a common
staple  food  when  feasible,  and  appropriate  iron  supplementation  for  infants  and
pregnant women. In all these intervention activities, operational research is needed to
improve effectiveness. In addition, controlling iron deficiency requires coordination
with other nutrition and primary health care programs as part of an integrated approach
to improved health and nutrition of the population. A randomized, controlled double-
blind clinical trial was conducted to compare the efficacy and safety of herbal medici‐
nal treatment syrup Sharbat-a-Folad versus syrup Ferplex for the treatment of iron
deficiency anemia (IDA).
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1. Introduction
Iron deficiency anemia (IDA) is the most common nutritional deficiency worldwide. It can cause
reduced work capacity in adults [1] and impact motor and mental development in children and
adolescents [2]. There is some evidence that iron deficiency without anemia affects cognition in
adolescent girls [3] and causes fatigue in adult women [4]. IDA may affect visual and auditory
functioning and is weakly associated with poor cognitive development in children.
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The term “anemia” is used for a group of conditions in which the number of red blood cells
in the blood is lower than normal, or the red blood cells do not have enough hemoglobin. The
estimates of the prevalence of anemia vary widely and accurate data are often lacking, and it
can be assumed that significant proportions of young children and women of childbearing age
are anemic [5, 6].
Iron deficiency results when iron demand by the body is not met by iron absorption from the
diet. Thus, patients with IDA presenting in primary care may have inadequate dietary intake,
hampered absorption, or physiologic losses in a woman of reproductive age. It also could be
a sign of blood loss, known or occult. IDA is never an end diagnosis; the work-up is not
complete until the reason for IDA is known.
The risk factors associated with IDA includes the following: low socioeconomic status, race as
black women have a lower mean hemoglobin and a wider standard deviation than white
women, inadequate dietary intake or parity, suggesting that there may be an unidentified,
possibly racial factor predisposing these women to iron deficiency [7].
Anemia cannot be reliably diagnosed by clinical presentation. Fatigue, the most common
reason to check hemoglobin, was caused by anemia in only one out of 52 patients in a primary
care practice [8]. In a hospital setting, pallor predicted anemia with a likelihood ratio (LR) of
4.5. However, the absence of pallor was less helpful in ruling out anemia, giving an LR of 0.6
even when anemia was defined as less than 9 g per dL (90 g per L), a lower diagnostic level
than that of the World Health Organization (WHO) or the Centers for Disease Control and
Prevention (CDC) [9]. Other classic symptoms such as koilonychia (spoon nails), glossitis, or
dysphagia are not common in the developed world [10].
The diagnosis of IDA requires that a patient be anemic and show laboratory evidence of iron
deficiency. Red blood cells in IDA are usually described as being microcytic (i.e., mean
corpuscular volume less than 80 μm3 [80 fL]) and hypochromic; however, the manifestation
of iron deficiency occurs in several stages [11]. Patients with a serum ferritin concentration less
than 25 ng per mL (25 mcg per L) have a very high probability of being iron deficient. The most
accurate initial diagnostic test for IDA is the serum ferritin measurement. Serum ferritin values
greater than 100 ng per mL (100 mcg per L) indicate adequate iron stores and a low likeli‐
hood ratio of IDA [12]. In some populations, such as those with inflammatory disease or
cirrhosis, these tests must be interpreted slightly differently because ferritin is an acute-phase
reactant. Cutoffs for abnormality in these patients generally are higher [13].
Another laboratory change that occurs in patients with IDA is an increase in the iron-carry‐
ing protein transferrin. The amount of iron available to bind to this molecule is reduced,
causing a decrease in the transferrin saturation and an increase in the total iron-binding
capacity. The serum transferrin receptor assay is a newer approach to measuring iron status
at the cellular level. Increased levels are found in patients with IDA, and normal levels are
found in patients with anemia of chronic disease [14].
The treatment arms were chosen by block randomization in batches of eight using computer-
generated random numbers to assign women to one of the four combinations of trial inter‐
vention. Block randomization was chosen to ensure that the experimental groups would not
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become unbalanced if the rate of recruitment at sites differed greatly. A research fellow with
no other role in the project is overseeing the labeling and packing of all the trial medications
and holding the randomization schedule until the code is broken.
1.1. Level of significance
This is the set standard to decide the cutoff value between treatment groups when compar‐
ing the two groups. If the results are significant at this set level (α = 0.05), the null hypothesis
will be rejected.
2. Patients, materials, and methods
2.1. Study design
The study was based on an experimental, randomized double-blind clinical trial. The study
had been conducted according to principles of good clinical practice (i.e., an informed consent
was obtained before enrollment and proper history and clinical examination were recorded
on each follow-up), and the study was carried out during May 2003 to June 2004. A random‐
ized double-blind experimental design was employed to test the hypotheses; therefore, by
manipulating the independent variables (efficacy, side effects), any effects on dependent
variable (herbal and allopathic treatment) could be monitored.
2.2. Patients
The study was conducted on 50 patients aged 12–40 years who were attending gynecologi‐
cal outpatient visits in Shifa-ul-Mulk Memorial Hospital.
2.3. Setting
The study was conducted in the Department of Gynecology and Obstetrics at Shifa-ul-Mulk
Memorial Hospital for Eastern Medicine at Hamdard University in Karachi.
2.4. Sample selection
In this study, only the patients selectively enrolled were diagnosed with IDA through clinical
history and laboratory investigations were enrolled. Diagnosis of IDA was based on the typical
signs and symptoms and laboratory finding. Complete blood picture (CBC), hemoglobin,
erythrocyte sedimentation rate (ESR), and urine (routine and microscopic) tests were also
performed.
Recruiting GPs identify eligible women in their clinical practice and invite them to consider
participation in the trial, after provision of sufficient information to make an informed decision.
Women who meet the eligibility criteria and agree to participate are required to give written
informed consent. Recruiting GPs also obtain demographic and relevant past and current
medical data, particularly data relevant to risk factors for developing iron deficiency anemia.
The interventions being tested are as follows:
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(i) Control group received allopathic treatment (syrup Ferplex two teaspoons for seven days),
(ii) and the test group received the herbal medicine (two teaspoons of syrup Foulad for seven
days). All participants were observed for three follow-up visits over the course of treatment
until they improved.
Blood samples were collected for CBC when the clinical picture shows the complete improve‐
ment to access the efficacy of the trial and confirmation and improvement in hemoglobin
status. Same parameters were followed in control group.
2.5. Assessment
The normal hemoglobin count in reference to age set standard of WHO, blood morphology,
was used as the primary outcome of the study. Secondary outcomes included the total
symptoms score, the global assessment of the treatment by the investigator, and the women
safety of the drugs and severity of adverse events at each follow-up visit. The relationship of
each event to the study drug was also assessed. The safety outcome measure was the inci‐
dence of treatment-emergent adverse events in both groups. A blood specimen for routine
CBC was obtained prior to the treatment.
2.6. Inclusion criteria
Persons may be included in the trial, if they meet the following criteria:
• Female patients between the aged of 12–40 years suffering from IDA.
• All socioeconomical classes were included.
• Verbal consent and willingness to participate in all scheduled study visits and tests.
• Patients suffering from IDA.
• Patients living in Karachi, Pakistan.
2.7. Exclusion criteria
Patients were excluded, if they have any of the following criteria:
• Patients having other associated pathologies such as uncontrolled diabetes, hypertension,
liver disorders, etc.
• Patients having other types of anemia such as protein deficiency anemia, pernicious anemia,
sickle cell anemia, and thalassaemia.
• Known cases of iron therapy failure.
• Patients suffering from iron deficiency in secondary to malignancies.
• Patient belonging to any area outside Karachi because of intrinsic difficulty to follow up.
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3. Results
The present study is to investigate formulated herbal medicine syrup Foulad for the treat‐
ment of IDA. The clinical screening of hematopoietic activity between Foulad and Ferplex was
carried out to determine the efficacy and side effects towards off this malaise. These evalua‐
tions were based on clinical and laboratory findings so as to ascertain the rate of improve‐
ment in hemoglobin. In this study, a total of 50 patients were initially randomized and
screened, the intent-to-treat population enrolled. The patients were evenly distributed to test
or control group with the ratio of 1:1, that is, 25 in each group. This loss was distributed evenly
between the treatment groups. The demographic and baseline characteristics of the intent-to-
treat group were comparable for the herbal medicine and allopathic medicine treatment.
3.1. Patient characteristics
There were no significant differences in the mean age (26.12 ± 7.92 vs. 26.48 ± 4.75 test and
control group, respectively, (Table 1) values between the treatment groups at the start of the
clinical trial. All the patients were distributed in five-class interval ranging from age 12 to 40
years. The mean age of the married women’s was 32.0 versus 32.46 and mean age of the single
patients was 19.75 versus 20.0.
Marital status Treatment group Mean Number (n) Standard deviation Sum
Married Control 32.46 13 4.75 422
Test 32.00 13 4.98 416
Total 32.23 26 4.78 838
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Marital status Treatment group Mean Number (n) Standard deviation Sum
Single Control 20.00 12 3.86 240
Test 19.75 12 5.17 237
Total 19.88 24 4.47 477
Total Control 26.48 25 7.65 662
Test 26.12 25 7.98 653
Total 26.30 50 7.74 1315
Table 1. Marital status by treatment group.
3.2. Treatment assignment and follow-up
All subjects were clinically studied and completed assigned therapy during the period May
2001 to June 2004. Results presented below represent an intention-to-treat analysis, as
stipulated by this study protocol. Baseline patient characteristics for all study variables were
balanced among treatment groups (Table 2).
Anemia history and examination at baseline Treatment group Total n = 50 pvalue
Control Test
Severity of anemia Mild 10 7 17 0.650
Moderate 12 15 27
Severe 3 3 6
Symptoms of anemia Asymptomatic 5 2 7 0.613
Fatigue 2 5 7
Reduced concentration 0 1 1
Loss of appetite 3 1 4
Pica 1 2 3
Signs of anemia Koilonychia 1 1 2
Brittle nails 1 0 1
Pallor 9 11 20
Tachycardia 3 2 5
Causes of anemia Blood loss 14 13 27 0.990
Decreased iron utilization 6 7 13
Dietary inadequacy 4 4 8
Malabsorption 1 1 2
Table 2. Baseline demographic variables.
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3.3. Baseline demographic variables
The baseline pretreatment analyses of IDA history and examination were performed. The
clinical evaluation proforma of IDA was filled at the time of enrollment in both treatment
groups. Patient’s baseline demographic variables for IDA history and general physical
examination were summarized for each treatment group. As depicted in Table 2, patient
characteristics were equally balanced between the test and control groups. The two treat‐
ment groups did not differ significantly (all p < 0.05) from each other at any time point. The
most common IDA symptom was pallor 44.0% in allopathic treated and 36.0% in herbal-treated
patients. Whereas the common cause of IDA noted in this trial was the blood loss 56% in
allopathic treated and 52% in herbal-treated patients.
3.4. Baseline severity of anemia
The assessment of severity of IDA at the time of enrollment exhibited following results test
group versus control group, mild anemia 7 patients (28%) versus 10 (40%), moderate anemia
15 patients (60%) versus 12 (48%), severe anemia 3 patients (12%) versus 3 (12%) patients
noticed in the both treatment groups. Baseline severity of anemia did not differ between the
two groups. Comparative analysis of the baseline data using chi-square test confirms that there
were no baseline differences among the treatment group as evident from p values in Table 2.
3.5. Effects of therapy on hemoglobin status
Hemoglobin increased dramatically in both treatment groups after therapy (as dissipated in
graph 2). The rates of the improvement in hemoglobin concentration were higher in the herbal
treatment group at all times after treatment and it revealed that the efficacy of herbal treat‐
ment is as superior to allopathic treatment (p = 0.001). The total duration of treatment was 4
weeks in both treatment groups. The clinical success rates on the basis of self-assessment of
patient regression of complaints and physician examination on follow-up were more effec‐
tive in test group (as in graph 2).
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Clinical failures or no significant improvement in hemoglobin after treatment occurred in 1/25
patients (4%) receiving herbal medicine and in 7/25 patients (28%) receiving allopathic
medicines (graph 2). Clinical success rates for those with mild-to-moderate infections and those
with severe infections were higher in test treatment group. For the overall, clinical success was
observed in 15/25 patients (60%) of cases in herbal-treated patients and in 2/25 (8%) of cases in
allopathic-treated patients.
The overall evaluation was mainly based on the efficacy of drugs in reducing anemia in terms
of both objective and subjective symptoms. The syrup Foulad produced a better result than
allopathic medicines, which showed an overall cure rate of 60% versus 8% significantly
effective as confirmed by chi-square test and the test treatment has superior efficacy than
control treatment (p = 0.001).
3.6. Safety evaluations
All the patients enrolled in the study were evaluated for safety. Adverse effects observed after
administration of medicine are summarized in Table 3. The majority of adverse events were
assessed as mild in severity. Adverse events categorized by the physician (researcher) as
possibly or definitely drug related were reported in 3/25 patients (12%) receiving herbal
medicine and in 15/25 patients (60%) given allopathic medicine.
Observed Side effects Treatment group Total p value
Control Test
Constipation 2 1 3 0.010
Diarrhea 3 1 4
Nausea 9 1 10
Vomiting 1 0 1
No complaints 10 22 32
Total patients 25 25 5
Table 3. Side effects on patient’s self-assessment.
Nausea was the most common drug-related events among allopathic medicine (36%) and
herbal group (4%) recipients. Overall side effects (p = 0.010) were greater in control-treated
participants than in test participants. No severe or serious adverse side effects were ob‐
served that interfere with activities of daily living. Comparison of data recorded by partici‐
pants relating to these variables showed highly significant differences between test and control
groups for measurements side effects as shown in Table 3.
Consequently, the generated data rejected the null hypothesis (when p < 0.05); hence, the null
hypothesis was rejected on the basis of statistical findings in regard to efficacy and safety.
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4. Discussion
Iron deficiency anemia (IDA) is most often a polysymptomatic disease. The use of allopathic
drug combination has been considered as one of the effective therapy. But this is not feasible,
as besides being cost prohibitive, they are not without side effects. The herbal formulation
syrup Foulad contains herbs, which are known for its wide range of clinical use in indige‐
nous medicine. It has been proved that these herbs exert profound activity for the improve‐
ment of hemoglobin percentage.
This unicenter trial demonstrated that herbal medicine was more effective in the manage‐
ment of patients with IDA. Herbal treatment resulted in a 60% clinical cure or improvement
rate, which is superior to that achieved with allopathic therapy 8% clinical success rate. The
response rate of hemoglobin improvement status before and after treatment suggests that
syrup Foulad has the higher efficacy as allopathic medicine (p > 0.001).
In light of study that the authors have presented, it is concluded that phytomedicine admin‐
istered under a randomized double-blind trial is exhibiting desirable effects with a profound
margin of safety. The plus point is that the formulations are absolutely cost-effective and have
shown promising results even in surveillance studies. The spectrum of herbal medicine has
been widening following the modalities of integrated medicine like our eastern system of
medicine.
The medicinal word is switching over to alternative medicine, including herbal medicine
especially South Asia, due to its tremendous potential that is being confirmed by current
researches. In this unicenter study, syrup Foulad was well tolerated and had a rate of drug-
related adverse events less than to that of patients treated with syrup Ferplex (p = 0.010). Mild
nausea was the most commonly reported adverse events in test treatment groups and control
group.
5. Conclusion
Based on the statistical result of present clinical trial, it can be concluded that
• a comparative evaluation of the IDA treatment by Sharbat Foulad vis-a-vis the syrup Ferplex
differs in treatment response, the herbal medicine is superior to allopathic medication.
• there was less untoward manifestation associated with the use of syrup Foulad and this is
found a good acceptability by most of the treated patients. Syrup Foulad has added the
benefit of safety.
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